On Friday, Kymera Therapeutics Inc (NASDAQ: KYMR) opened lower -6.49% from the last session, before settling in for the closing price of $77.81. Price fluctuations for KYMR have ranged from $19.44 to $103.00 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -26.36% over the past five years. Company’s average yearly earnings per share was noted -17.54% at the time writing. With a float of $65.71 million, this company’s outstanding shares have now reached $71.74 million.
Kymera Therapeutics Inc (KYMR) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Kymera Therapeutics Inc is 16.77%, while institutional ownership is 91.58%. The most recent insider transaction that took place on Dec 31 ’25, was worth 2,341,939. In this transaction Chief Executive Officer of this company sold 30,000 shares at a rate of $78.06, taking the stock ownership to the 663,077 shares. Before that another transaction happened on Dec 31 ’25, when Company’s Officer proposed sale 30,000 for $77.69, making the entire transaction worth $2,330,700.
Kymera Therapeutics Inc (KYMR) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.89 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.79) by -0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.97 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -17.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -11.34% during the next five years compared to -26.36% drop over the previous five years of trading.
Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators
Check out the current performance indicators for Kymera Therapeutics Inc (KYMR). In the past quarter, the stock posted a quick ratio of 7.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 131.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.60, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -3.69 in one year’s time.
Technical Analysis of Kymera Therapeutics Inc (KYMR)
As of the previous 9 days, the stock’s Stochastic %D was 5.87%.
During the past 100 days, Kymera Therapeutics Inc’s (KYMR) raw stochastic average was set at 53.78%, which indicates a significant increase from 3.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 3.49 in the past 14 days, which was higher than the 2.99 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $70.42, while its 200-day Moving Average is $48.49. Nevertheless, the first resistance level for the watch stands at $76.34 in the near term. At $79.92, the stock is likely to face the second major resistance level. The third major resistance level sits at $82.01. If the price goes on to break the first support level at $70.67, it is likely to go to the next support level at $68.58. Assuming the price breaks the second support level, the third support level stands at $65.00.
Kymera Therapeutics Inc (NASDAQ: KYMR) Key Stats
There are currently 71,949K shares outstanding in the company with a market cap of 5.74 billion. Presently, the company’s annual sales total 47,070 K according to its annual income of -223,860 K. Last quarter, the company’s sales amounted to 2,760 K and its income totaled -82,180 K.
